Show simple item record

Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire

dc.contributor.authorChung, Lorindaen_US
dc.contributor.authorChen, Huberten_US
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorSteen, Virginia D.en_US
dc.date.accessioned2013-03-05T18:17:49Z
dc.date.available2014-05-01T14:28:12Zen_US
dc.date.issued2013-03en_US
dc.identifier.citationChung, Lorinda; Chen, Hubert; Khanna, Dinesh; Steen, Virginia D. (2013). "Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire." Arthritis Care & Research 65(3): 454-463. <http://hdl.handle.net/2027.42/96723>en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/96723
dc.description.abstractObjective The University of California in San Diego Shortness of Breath Questionnaire (UCSD SOBQ) has been used to assess dyspnea‐related activity limitation in patients with airway and parenchymal lung disease. We sought to assess the construct validity and responsiveness of the UCSD SOBQ in systemic sclerosis (SSc; scleroderma) patients with incident pulmonary hypertension (PH) and those at high risk of developing PH. Methods We used data from 179 patients enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry with pre‐PH (defined by criteria on pulmonary function tests and/or echocardiogram) or definite PH with mean pulmonary artery pressure ≥25 mm Hg by right‐sided heart catheterization within 6 months of enrollment. For this analysis, we included those subjects with complete data for self‐reported measures at baseline and at 12 months. Results At baseline, the UCSD SOBQ had strong correlations in the expected direction with the disability index (DI) of the Health Assessment Questionnaire (HAQ) (r = 0.71, P < 0.0001), dyspnea assessment by visual analog scale (r = 0.71, P < 0.0001), and the Short Form 36 (SF‐36) health survey physical component summary (PCS) score (r = −0.77, P < 0.0001), as well as a moderate correlation with the 6‐minute walk test distance (r = −0.33, P < 0.0001), Borg dyspnea score (r = 0.47, P < 0.0001), and diffusing capacity of carbon monoxide (r = −0.33, P < 0.0001). Change in the UCSD SOBQ at 12 months correlated in the expected direction with change in the HAQ DI (r = 0.54, P < 0.0001) and change in the SF‐36 PCS (r = −0.44, P < 0.0001). Multivariate analysis adjusting for age, sex, and race identified male sex as a significant predictor of death (odds ratio [OR] 7.00, 95% confidence interval [95% CI] 1.55–31.76), while the UCSD SOBQ showed a strong trend toward significance (OR 1.82, 95% CI 0.97–3.41). Conclusions The UCSD SOBQ demonstrates good construct validity and responsiveness to change in SSc patients with pulmonary vascular disease.en_US
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.titleDyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaireen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationotherStanford University and VA Palo Alto Health Care System, Palo Alto, Californiaen_US
dc.contributor.affiliationother3801 Miranda Avenue, VA Palo Alto Health Care System, Palo Alto, CA 94305en_US
dc.contributor.affiliationotherGeorgetown University, Washington, DCen_US
dc.contributor.affiliationotherUniversity of California, San Francisco, and Genentech, San Francisco, Californiaen_US
dc.identifier.pmid23042670en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/96723/1/21827_ftp.pdf
dc.identifier.doi10.1002/acr.21827en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceSekhon S, Pope J, Baron M. The minimally important difference in clinical practice for patient‐centered outcomes including Health Assessment Questionnaire, fatigue, pain, sleep, global visual analog scale, and SF‐36 in scleroderma. J Rheumatol 2010; 37: 591 – 8.en_US
dc.identifier.citedreferenceKupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005; 25: 370 – 7.en_US
dc.identifier.citedreferenceJohnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire disability index and Scleroderma Health Assessment Questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005; 53: 256 – 62.en_US
dc.identifier.citedreferenceRannou F, Poiraudeau S, Berezne A, Baubet T, Le‐Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36‐Item Short Form Health Survey. Arthritis Rheum 2007; 57: 94 – 102.en_US
dc.identifier.citedreferenceWare JE, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care 1992; 30: 473 – 83.en_US
dc.identifier.citedreferenceGliddon AE, Dore CJ, Maddison PJ, and the Quins Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006; 55: 473 – 9.en_US
dc.identifier.citedreferenceKhanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al. Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592 – 600.en_US
dc.identifier.citedreferenceKhanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF‐36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832 – 40.en_US
dc.identifier.citedreferenceKhanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007; 56: 1676 – 84.en_US
dc.identifier.citedreferenceCohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.en_US
dc.identifier.citedreferenceGilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009; 135: 137 – 42.en_US
dc.identifier.citedreferenceKhanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D‐penicillamine study. Ann Rheum Dis 2006; 65: 1325 – 9.en_US
dc.identifier.citedreferenceBoers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25: 198 – 9.en_US
dc.identifier.citedreferenceBellamy N. Clinimetric concepts in outcome assessment: the OMERACT filter. J Rheumatol 1999; 26: 948 – 50.en_US
dc.identifier.citedreferenceBaron M, Sutton E, Hudson M, Thombs B, Markland J, Pope J, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008; 67: 644 – 50.en_US
dc.identifier.citedreferenceHinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, et al. Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐Reported Outcomes Measurement Information System 29‐item Health Profile and Functional Assessment of Chronic Illness Therapy–Dyspnea short form. Arthritis Care Res (Hoboken) 2011; 63: 1620 – 8.en_US
dc.identifier.citedreferenceBeretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health‐related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 2007; 46: 296 – 301.en_US
dc.identifier.citedreferenceRies AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2: 105 – 10.en_US
dc.identifier.citedreferenceBouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581 – 6.en_US
dc.identifier.citedreferenceHissaria P, Lester S, Hakendorf P, Woodman R, Patterson K, Hill C, et al. Survival in scleroderma: results from the population‐based South Australian Register. Int Med J 2011; 41: 381 – 90.en_US
dc.identifier.citedreferenceFransen J, Popa‐Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5‐year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788 – 92.en_US
dc.identifier.citedreferenceFisher MR, Mathai SC, Champion HC, Girgis RE, Housten‐Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma‐related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043 – 50.en_US
dc.identifier.citedreferenceSteen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972‐2002. Ann Rheum Dis 2007; 66: 940 – 4.en_US
dc.identifier.citedreferenceWigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward‐Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community‐based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 2125 – 32.en_US
dc.identifier.citedreferenceMukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088 – 93.en_US
dc.identifier.citedreferenceHachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792 – 800.en_US
dc.identifier.citedreferenceChung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease‐associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383 – 94.en_US
dc.identifier.citedreferenceHinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172 – 9.en_US
dc.identifier.citedreferenceAvouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290 – 8.en_US
dc.identifier.citedreferenceWilliams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N‐terminal brain natriuretic peptide (NT‐proBNP) in scleroderma‐associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485 – 94.en_US
dc.identifier.citedreferenceCavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L, et al. Comparison of brain natriuretic peptide (BNP) and NT‐proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064 – 70.en_US
dc.identifier.citedreferenceEakin EG, Sassi‐Dambron DE, Ries AL, Kaplan RM. Reliability and validity of dyspnea measures in patients with obstructive lung disease. Int Behav Med 1995; 2: 118 – 34.en_US
dc.identifier.citedreferenceEakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire, University of California, San Diego. Chest 1998; 113: 619 – 24.en_US
dc.identifier.citedreferenceRies AL. Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med 2006; Suppl 1: 12 – 20.en_US
dc.identifier.citedreferenceSwigris JJ, Yorke J, Sprunger DB, Swearingen C, Pincus T, du Bois RM, et al. Assessing dyspnea and its impact on patients with connective tissue disease‐related interstitial lung disease. Respir Med 2010; 104: 1350 – 5.en_US
dc.identifier.citedreferenceFries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137 – 45.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.